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Atopic dermatitis
Atopic dermatitis (AD) is a common chronic relapsing
inflammatory skin disease, characterized by intense
itching, dry skin, inflammation and exudation. It causes
physical and emotional distress for patients and their
families. The first symptoms commonly develop in
infancy, with around 50% of cases diagnosed by 1 year
of age,1 and AD is typically a long-term condition with
at least one-third of patients having persistent disease
throughout adulthood. However the vast majority of
cases of atopic dermatitis are mild in severity and
usually can be managed easily.2 The disease is often
familial and frequently associated with asthma, food
allergy, allergic rhinitis and recurrent secondary skin
infections. Atopic dermatitis has significant impact on
quality of life in both children3 and adults.4 The impact
is greater than with psoriasis and is equivalent to other
serious medical conditions such as early onset of
diabetes mellitus.5 The prevalence of atopic dermatitis
has increased steadily in recent decades.4 In developed
countries approximately 10–15% of children under
5 years of age are affected at some stage.4 The likelihood
is that 60% of children with atopic dermatitis may
recover free of the disease, the remainder having
recurrences for long periods of time.6 It has also been
suggested that the best prognosis for the disease is in
those children who developed AD in the first year of life.7
However, overall the earlier the onset and the more
severe the disease, there is a greater chance of persist-
ence, especially with concurrent atopic disorders.
Recent evidence has indicated a common pathophysi-
ological link between severe atopic dermatitis, asthma
and allergic rhinitis8,9 (for example both asthma and AD
are associated with increased IgE and eosinophilia). It
has been suggested that atopic dermatitis may increase
the subsequent risk or severity of asthma.10
Current management of atopic dermatitis
At present there is no 100% life-long cure for atopic
dermatitis. Management comprises a disease adapted
treatment combining adjuvant basic therapy (skin
protection) and, if needed, anti-inflammatory measure-
ments and the identification and avoidance of trigger
factors.11,12 Treatment currently focuses on sympto-
matic relief (skin hydration and reduction of pruri-
tus).13–15
Therapeutic options
Adjuvant basic therapy As the barrier function of the
skin in patients with atopic dermatitis is impaired, an
adjuvant basic therapy is essential in the management
of this disease consisting of the regular application of
adequate moisturizers. Different classes of moisturisers
are based on their mechanism of action, including
occlusives, humectants, emollients and protein rejuve-
nators. Patients may be prescribed different moisturiz-
ers depending on their particular preference, their age
and their type of eczema. Emollients keep the skin
hydrated and can reduce itching. They should be
applied regularly at least twice during the day, even
when there are no symptoms of disease and should also
be applied after swimming or bathing.
Topical steroids as the current standard for anti-inflamma-
tory therapy Intermittent use of topical corticosteroids
to treat the signs and symptoms of atopic dermatitis, in
conjunction with emollients, has been the standard
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disease management. Topical corticosteroids are often
prescribed intermittently for short-term reactive treat-
ment of acute flares and supplemented by emollients.
Reactive treatment with corticosteroids offers rapid and
effective symptomatic relief for acute flares. However,
there are considerable safety concerns associated with
their use, particularly when they are applied continu-
ously. Potential adverse events are primarily cutaneous
(principally skin atrophy, but also telangiectasia,
hypopigmentation, steroid acne, increased hair
growth and rosacea-like eruptions), but there may be
systemic effects (suppression of the hypothalamic-
pituitary-adrenal (HPA) axis, growth retardation,
increased risk of glaucoma cataract and Cushing’s
syndrome).16–20 These safety concerns have led to
restrictions on the intensity and duration of topical
corticosteroid use, especially in children and on delicate
skin areas such as the face, neck and skin folds.
Topical corticosteroids may be a challenge to use.
Patients or parents may be concerned about side-
effects. The numerous products, and where to apply
each specifically, may confuse patients. Generic prod-
ucts appear to patients to have different names, even
though the active molecule is the same; patients may
be guessing which product to use. The generic product
may have different potency than the brand product
when put into clinical use.
Other treatment options
A range of other treatment options is available for
atopic dermatitis, including systemic corticosteroids or
other pharmacological interventions such as cyclo-
sporine21 or azathioprine. These are generally reserved
for severe cases that prove refractory to conventional
treatment with topical agents. Long-term treatment
with mycophenolate mofetil has also been successfully
used in severe atopic dermatitis.22
Sedating antihistamines may be used for intense
pruritus causing sleep disturbance. Physical therapies
such as phototherapy and wet wraps are also
employed in some instances. Intermittent use of topical
and oral antibiotics can be helpful in cases where
S. aureus overgrowth is prominent.23 Appropriate
counseling may be offered to patients in whom atopic
dermatitis is exerting a pronounced psychological
impact.
There is considerable dissatisfaction with existing
standard pharmacological and physician interven-
tions14,24,25 and some patients explore ‘alternative’
therapies, such as Chinese herbal remedies, homeopathy
or acupuncture, although there is limited evidence to
evaluate their effectiveness.26
Avoidance of trigger factors
Atopic dermatitis can be provoked by a number of
trigger factors. Among these are irritants (inappropri-
ate clothing, water hardness, etc.), microbes (especially
Staphylococcus aureus), psychological (especially stress
situations) and allergic factors. Atopic dermatitis
patients often have raised serum IgE levels and a high
degree of sensitization to environmental allergens
including foods. Indoor or outdoor pollutants such as
tobacco smoke influence IgE production.9 Up to one-
third of children with atopic dermatitis may have a
coexisting food allergy.27 Trigger factors should if
possible be identified and avoided. However, further
research is needed to more clearly identify triggers as
well as avoidance tactics. Allergological investigations
rarely have therapeutic consequences in mild to
moderate cases of atopic dermatitis.
Limitations of current treatment strategies
In many patients, the atopic dermatitis is poorly
controlled. Topical corticosteroids are often reserved
for flares that have become fully manifest. Lack of
confidence in corticosteroid safety also adversely
affects compliance and under-treatment of children
with atopic dermatitis is common owing to physicians’
and parents’ concerns about the side-effects of corti-
costeroids.24 Systemic treatment is associated with
potentially severe adverse effects and is not recom-
mended except as a last resort.14 Phototherapy is
inconvenient and may carry a risk of future skin
cancers and ⁄ or photoageing. The immunosuppres-
sants, including cyclosporine and azathioprine, require
appropriate monitoring because of their potential
effects on organ toxicity, increased risk of infection
and possibly lymphoma and may interfere with
immunization during childhood. There is also a need
for controlled studies with allergen-specific immuno-
therapy, where some benefit has been shown in atopic
dermatitis.
Therapeutic objectives for atopic dermatitis
In the absence of a cure, the therapeutic objectives for
atopic dermatitis can be defined as follows:
• reduce signs and symptoms;
• prevent or reduce recurrences;
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• provide long-term management by preventing
exacerbation;
• modify the course of the disease.
Conventional therapies focus on the reactive treat-
ment of relapses. There is a need for new safe and
effective therapies for early control and long-term
maintenance.
New developments: the role of new and
emerging treatments
New and emerging therapies such as the topical
calcineurin inhibitors, tacrolimus and pimecrolimus,
not only complement existing treatment options but
also overcome some of the drawbacks of topical steroid
therapy and fulfil the long-term needs of patients in
preventing disease progression. Their primary mech-
anism of action, which is distinct from topical corti-
costeroids, is to inhibit inflammatory cytokine
transcription in activated T cells and other inflamma-
tory cells through inhibition of calcineurin.28,29
Unlike many corticosteroids, these agents may be
used on all body locations for extended periods. Their
potencies are standard and there are no generic
substitutes. Skin atrophy, glaucoma, and other local
risks of corticosteroids do not occur, nor do the
systemic side-effects such as HPA-axis suppression
and growth retardation.
Pimecrolimus
Pimecrolimus exhibits high anti-inflammatory activity
in models of skin inflammation,28–30 but has only low
activity in models of systemic immunosuppression.30,31
Pimecrolimus 1% cream, specifically developed for the
treatment of inflammatory skin diseases, has been
shown to offer a safe and effective treatment option in a
broad spectrum of atopic dermatitis patients, including
infants,32 children33 and adults34–36 with mild-
to-severe disease even in highly sensitive skin
areas.37,38 More importantly (when used in the early
stages) it has also been proven to have significant
therapeutic advantages over conventional therapy
(emollients plus topical corticosteroids) in the long-
term management of atopic dermatitis.39
The results from short-term37,40,41 and long-term42
controlled clinical trials demonstrate its rapid and
sustained effect in controlling pruritus, which is the
primary complaint of patients with atopic dermatitis
and is often the main indication for use of corticoster-
oids. In the controlled long-term study in adults43 a
significant effect (P < 0Æ001), of pimecrolimus treat-
ment on pruritus relief could be seen as early as Day 3
when compared to a conventional treatment. Relief
from pruritus with pimecrolimus cream is also demon-
strated across a diverse patient population in terms of
age (> 3 months)40 and severity of disease.43 Pimecro-
limus also provides significantly better long-term
control of atopic dermatitis than a conventional
treatment by preventing progression of disease to
flare.43–45 In large, controlled studies, significantly
more patients in the pimecrolimus groups remained
flare-free at 6 and 12 months when compared to a
conventional-treatment group. For example, in the
pimecrolimus group, 61% of patients remained flare-
free during the first 6 months of the study in contrast
to only 34% of patients treated conventionally
(P < 0Æ001).44 The beneficial effect of pimecrolimus
cream is also sustained over time with 51% of
pimecrolimus patients vs. 28% in the conventional
treatment group remaining flare-free at 12 months
(P < 0Æ001).44 The ability of pimecrolimus to prevent
flare progression also results in a significant steroid-
sparing effect.43–45 In a large study in infants, 64% of
pimecrolimus patients required no steroids throughout
the 12 months of the study, compared to 35% of those
subjects treated conventionally.45
The potential for pimecrolimus to prevent flare
progression and improve disease control is confirmed
by a clear trend towards a significant reduction in use
of pimecrolimus over time, which was seen in both
large, long-term paediatric studies.44,45
Tacrolimus
Topical tacrolimus, an ointment formulation46 of the
oral systemic immunosuppressive agent used to pre-
vent allotransplant rejection, has shown efficacy and
safety for the treatment of atopic dermatitis in both
short-term, double-blind47 and long-term, open-label48
clinical studies.
Tacrolimus ointment has a rapid and sustained effect
on signs and symptoms of atopic dermatitis in adults49
and children50 with moderate-to-severe atopic derma-
titis. In two long-term, open-label studies48,49 an
improvement was seen in all symptomatic parameters
after 1 week of therapy. This improvement was main-
tained over 12 months.
The ability of tacrolimus ointment to clear atopic
dermatitis was investigated in two short-term, vehicle
controlled studies. In one study, 41% of patients treated
with 0Æ1% tacrolimus ointment had ‡ 90% clearance
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of disease at the end of the 12 weeks compared to only
7% in the vehicle treatment group (P < 0Æ001).49
Two recent short-term (3-week) studies, in children
(2–15 years)51 and adults52 with moderate-to-severe
AD compared tacrolimus ointment (0Æ1% and 0Æ03%)
and conventional treatment with a topical corticoster-
oid. In adults, tacrolimus was compared with a topical
corticosteroid of mid-potency, hydrocortisone-17-buty-
rate ointment 0Æ1%. In children, the comparator was
the low-potency hydrocortisone acetate ointment 0Æ1%.
The results confirmed the efficacy of tacrolimus oint-
ment compared to these topical corticosteroids and
showed a quick onset of efficacy. In the study with
children, there was a trend for the 0Æ1% tacrolimus to
be more effective than 0Æ03% tacrolimus and for both
formulations to be more effective than hydrocortisone
acetate.51 There were no serious safety concerns in
either trial, with the only significant adverse event
being transient skin burning and irritation.
This, together with the clinical data from pimecrol-
imus, reinforces the role of topical calcineurin inhibi-
tors as maintenance therapy for atopic dermatitis with
corticosteroids being reserved for acute control of
disease progression.
Safety of the new treatments
Pre-clinical and clinical findings
When discussing safety of the new topical calcineurin
inhibitors, two aspects have to be considered:
• potential systemic exposure due to percutaneous
absorption;
• and local adverse events.
Percutaneous absorption of tacrolimus in healthy
volunteers has been shown to be generally low.53
Although in patients with atopic dermatitis, tacrolimus
blood levels have been shown to be dose-dependent,54
broadly related to the severity of the disease and degree
of lichenification the majority had low tacrolimus blood
levels and these have shown to decrease over time.54–56
Systemic blood levels of pimecrolimus have been
shown to be consistently low and independent of
duration of therapy (3 weeks to 1 year) and age of
patients. There were no significant increases in sys-
temic blood levels with increasing extent of body
surface involvement (up to 92% TBSA).57 As with
tacrolimus, no long-term accumulation has been
reported with pimecrolimus.36,57 In the clinical trials
both pimecrolimus and tacrolimus have shown no
significant systemic toxicity.43–45,55,56
Skin atrophy, a local adverse event, long associated
with topical corticosteroids, was not seen in any of the
clinical trials with pimecrolimus or tacrolimus. In
contrast to topical corticosteroids, tacrolimus and
pimecrolimus have been shown to be also safe for
application to particularly sensitive areas such as the
face and neck.56,57
The most common important local-site reaction with
topical tacrolimus and pimecrolimus is local discomfort
associated with the application of the drug. In the
tacrolimus clinical trials (with 0Æ03% ointment) up to
36% of paediatric patients58–60 and up to 47% of adult
patients47,58 exposed to the study medication experi-
enced a local burning sensation at time of application.
Pimecrolimus cream 1% demonstrated a comparable
level of application-site burning to conventional treat-
ment with only 7Æ4% vs. 7Æ4%, respectively, reporting
burning sensation in the long-term paediatric stud-
ies.61 Also, in adult patients 10Æ4% of the pimecrolimus
group experienced application-site burning compared
to 3Æ1% in the conventional treatment group.43 Appli-
cation site burning is, however, transient and of short
duration.
Given the mechanism of action, the possibility of
local immunosuppression with topical tacrolimus and
pimecrolimus is a potential concern. However, the risk
of local bacterial infections is less in patients treated
with topical calcineurin inhibitors than in patients on
topical corticosteroids.62 It is important to note that
corticosteroids act on a broad spectrum of immune
competent cells, including Langerhans’ cells that have
a key function in the local immunosurveillance. In
clinical studies with pimecrolimus secondary skin
infections occurred at similar rates as those patients
treated with placebo.45 With both compounds there is a
decreased rate of skin infection over increasing length
of use.45,63
With tacrolimus ointment in a 52-week photocar-
cinogenicity study, the median time to onset of skin
tumour formation was decreased in hairless mice as
compared to vehicle-treated animals, following chronic
topical dosing with concurrent exposure to UV radi-
ation (40 weeks of treatment followed by 12 weeks of
observation) with tacrolimus ointment.64 The risk of
photocarcinogenicity is still undetermined in humans.
In a similar study with pimecrolimus, there was a
decrease in median time to onset, with vehicle cream
alone, but this was unchanged with the addition of
pimecrolimus.65 It is nevertheless prudent for patients
to minimize natural or artificial sunlight exposure
whilst using the topical treatments.
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In summary, the new topical calcineurin inhibitors
seem to be extremely safe without many of the side-




The treatment of atopic dermatitis must be based on an
initial assessment of disease history, extent, and sever-
ity, including assessment of psychological distress and
impact on the family (Fig. 1). The physician)patient
communication is of utmost importance to secure
compliance with treatment.
The initial treatment of atopic dermatitis consists of
the liberal use of emollients for skin hydration. This
should be coupled with education for both patients and
caregivers on the avoidance of trigger factors.
Also, when the patient is already in flare, short-term
use of topical corticosteroids is indicated to treat the
acute disease. Topical calcineurin inhibitors are alter-
natives for acute control of pruritus and inflammation.
Once the condition settles they can then revert to
continuous use of emollients.
For maintenance therapy (in the case of persistent
disease or frequent recurrences), topical calcineurin
inhibitors can be used as well (Fig. 1). Pimecrolimus
was used in clinical studies at the first sign or symptom
of atopic dermatitis. It has been proven to prevent
disease progression43–45 and reduce the incidence of
flares, with corticosteroids being reserved for acute
exacerbations. Once the patient is back in remission
emollients should be continued. It should be noted that
the currently available data demonstrate that pimecr-
olimus can prevent flare progression. Tacrolimus stud-
ies have shown efficacy in long-term atopic eczema
therapy,47,48 but its effect on incidence of flares has not
been studied.
Use as described above is possible because of the safety
profile established in long-term trials of topical cal-
cineurin inhibitors together with the proven ability of
pimecrolimus to prevent progression of disease and
improve disease control compared to conventional treat-
ment (topical corticosteroids and emollients).43–45 It
also optimizes the role of corticosteroids, which are
highly efficacious in treating acute exacerbations,
whilst minimizing the risks by decreasing the time for
which they are used.
Additional benefits of the treatment recommenda-
tions:
• it is easily communicated to patients;
• different areas of the skin can be treated in different
ways depending on the activity of the condition;
• development of a clearly understood and effective
treatment strategy should minimize the likelihood of
patients seeking alternative and unproven therapies;
• this approach should help to standardize or harmon-
ize the evaluation and treatment of the patient across
clinical specialties;
• the treatment algorithm complements but extends
current practice by allowing more individualization
of treatment according to patient need.
Adjunctive therapy
In conjunction with drug treatment, adjunctive meas-
ures may also be necessary to maximize the outcome
for individual patients. This may range from education
on the avoidance of trigger factors to providing
psychological support.
Infections can alter the course of the disease. In the
event of patients developing either a bacterial, fungal or
viral skin infection, the infection needs to be fully
evaluated and appropriate antibiotic, antifungal or
antiviral therapy should be initiated as soon as possible.
Before commencing treatment with anti-inflammatory
agents, clinical infections at treatment sites should be
cleared.
Special emphasis should be put on treating reservoirs
of the disease, i.e. nose and the groin, to prevent
recurrence.
If the symptoms of atopic dermatitis are refractory
and the condition cannot be brought under control by
treatment with topical calcineurin inhibitors and inter-
mittent use of corticosteroids, a range of options could
be considered depending on the status of the individual
patient. These include phototherapy, drug therapy with
more potent topical or oral steroids, immunosuppres-
sants such as cyclosporin, methotrexate or azathiop-
rine alone or in combination with psychotherapeutic
and psychopharmacological options.
In conclusion, there is a need for an effective and safe
therapy for early control and long-term maintenance of
atopic dermatitis, irrespective of the age of the patient.
Topical corticosteroids have been the standard of
therapy for many years and while their efficacy is not
in question there are continuing concerns about their
safety. The new class of topical calcineurin inhibitors
may fulfil this unmet need by providing a safe
and effective option for the long-term control of atopic
dermatitis.
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These new treatments for atopic dermatitis are
welcomed by patients, parents of patients, and physi-
cians including dermatologists and paediatricians, as
another treatment option for this demoralizing disease,
and the first major advance in its management in half a
century.
Figure 1. Algorithm for treatment of atopic dermatitis.
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